• Homoharringtonine: Mechanism to Assay Design

  2026-08-22

  Homoharringtonine is a cytotoxic alkaloid whose ribosome-level activity connects leukemia research with emerging SARS-CoV-2 antiviral research. This guide focuses on translating its mechanism into rigorous, compartment-aware assay design and evidence interpretation.

• Primidone: TRPM3 and RIPK1 Research Workflows

  2026-08-21

  Primidone, also known as Mysoline, connects TRPM3 channel inhibition with RIPK1-focused neurodegeneration and pain research. This practical guide covers concentration selection, animal model dosing, assay controls, formulation, and troubleshooting for reproducible translational studies.

• EdU Imaging Kits (488): Practical Workflow

  2026-08-20

  EdU Imaging Kits (488) turn S-phase DNA synthesis into a sensitive fluorescence readout for microscopy and flow cytometry without harsh DNA denaturation. This guide shows how to apply the assay to proliferation studies, including translational evaluation of emerging glioblastoma therapies such as implantable Tumor Treating Fields.

• Z-VAD-FMK: Reframing Apoptosis and Necroptosis

  2026-08-20

  Z-VAD-FMK is more than a broad apoptosis inhibitor: it is a causal tool for separating caspase-dependent death from necroptosis. This translational framework connects inhibitor selection, lysosomal membrane permeabilization, MLKL polymerization, and reproducible pathway validation.

• Topotecan: Pharmacology, Mechanism, and Clinical Evidence

  2026-08-19

  The 1999 review by Kollmannsberger and colleagues presents topotecan as a water-soluble camptothecin derivative that stabilizes DNA–topoisomerase I cleavable complexes and produces replication-associated DNA damage. Its synthesis of pharmacokinetic, toxicity, scheduling, and early clinical data explains both the drug’s activity in ovarian and small-cell lung cancers and the unresolved questions surrounding renal dosing and combination therapy.

• Ionisable Lipid and Sterol Effects in LNPs

  2026-08-19

  The 2025 Journal of Controlled Release study systematically compares proprietary ionisable lipids with ALC-0315 to show how lipid structure influences LNP physicochemical properties, mRNA expression, and tissue distribution. Its main practical implication is that in vitro performance cannot substitute for route-specific in vivo evaluation, while ionisable lipid chemistry generally has a stronger influence on mRNA delivery than sterol selection.

• U-73122: Phospholipase C Inhibitor Guide

  2026-08-18

  U-73122 is a phospholipase C inhibitor used to interrogate PLC signaling pathway modulation, calcium flux, chemotaxis, inflammation, and cancer-cell invasion. Product data report approximately micromolar cellular activity, while a breast cancer study links U73122 treatment with reversal of QPRT-associated invasion and myosin light-chain phosphorylation.

• Dextran sulfate sodium salt in DSS Colitis Models

  2026-08-18

  Learn how Dextran sulfate sodium salt (MW 35000-45000) creates a controlled intestinal injury platform for epithelial-barrier research, therapeutic screening, and repair biology. The workflow connects DSS-induced damage with the GPR35-KLF5 repair circuit while emphasizing dose control, recovery-phase sampling, and troubleshooting.

• Forsythoside E: A PKM2 Assay Design Guide

  2026-08-17

  Forsythoside E is a mechanistically distinctive pyruvate kinase M2 (PKM2) inhibitor for studying macrophage immunometabolism. This guide connects target engagement, glycolytic remodeling, STAT3 signaling, and assay design while defining the limits of current sepsis-liver injury evidence.

• Forsythoside E: PKM2 Workflow Guide

  2026-08-17

  Forsythoside E connects PKM2 tetramerization with macrophage metabolism, STAT3 signaling, and sepsis-induced liver injury research. This practical guide translates its binding and dosing data into assay design, formulation control, and troubleshooting decisions.

• EdU Imaging Kits (488) for Tumor Cell-Cycle Studies

  2026-08-16

  EdU Imaging Kits (488) translate DNA-replication activity into a sensitive, imageable readout for cancer and cell-cycle experiments. This guide shows how to pair 5-ethynyl-2'-deoxyuridine labeling with microscopy or flow cytometry when evaluating emerging therapies such as implantable Tumor Treating Fields.

• TAK1–YAP Stabilization in Gastric Cancer Stem Cells

  2026-08-15

  The reference study identifies TGFβ-activated kinase 1 (TAK1) as a promoter of gastric cancer stem-cell self-renewal and tumorigenesis through stabilization of YAP. Its evidence connects IL-6, TAK1–YAP interaction, and SOX2/SOX9 transcription, providing a mechanistic framework for studying gastric cancer stemness and treatment resistance.

• Linarin, Cyclin A2, and NSCLC Cell-Cycle Arrest

  2026-08-14

  A 2026 study identifies the Herba Patriniae flavonoid linarin as an inhibitor of NSCLC growth that induces G0/G1 arrest, senescence, and apoptosis in both p53-wild-type and p53-null models. Its integrated use of network pharmacology, phenotypic assays, molecular docking, and protein analysis links these effects to reduced CCNA2, CCNB1, and CHEK1 signaling, while also illustrating how DNA-synthesis measurements can strengthen cell-cycle studies.

• Novel Allosteric PDK4 Inhibitors: Study Insights

  2026-08-14

  The reference study used anthraquinone scaffold optimization to identify compound 8c, a new allosteric pyruvate dehydrogenase kinase 4 inhibitor with nanomolar biochemical activity and activity across metabolic, allergic, and cancer models. Its combination of biochemical testing, drug-metabolism evaluation, molecular docking, and mouse studies provides a useful framework for assessing PDK4-directed metabolic modulation while also highlighting the limits of translating early efficacy findings.

• DHEA as a Mechanistic Probe in Ovarian Research

  2026-08-13

  Explore how Dehydroepiandrosterone (DHEA) can be used to dissect immune–granulosa cell interactions, apoptosis, and ovarian dysfunction. This article translates recent CD163 findings into practical assay-design decisions while also defining the limits of DHEA-based neuroprotection and PCOS models.

8600 records 10/574 page Previous Next First page 上5页 678910 下5页 Last page